Background & Aims: Non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes mellitus (T2DM) are closely associated, and liver fibrosis has been related to macrovascular complications. We examined whether liver fibrosis, diagnosed by FibroScan®, correlates with chronic vascular complications in a cohort of T2DM. Methods: We recruited 394 outpatients with T2DM attending five Italian diabetes centres who underwent liver ultrasonography (US), FibroScan® and extensive evaluation of macrovascular and microvascular diabetic complications. Results: Steatosis by US was present in 89%. Almost all patients (96%) were on hypoglycaemic drugs, 58% had at least one chronic vascular complication, 19% a macrovascular complication (prior myocardial infarction and/or ischaemic stroke) and 33% a microvascular one (26% chronic kidney disease [CKD]; 16% retinopathy; 6% neuropathy). In all, 171 (72%) patients had CAP ≥ 248dB/m (ie hepatic steatosis), whereas 83 (21%) patients had LSM ≥ 7.0/6.2 kPa (M/XL probes) (significant liver fibrosis). CAP was not associated with any macro/microvascular complications, whereas LSM ≥ 7.0/6.2 kPa was independently associated with prior cardiovascular disease (adjusted OR 3.3, 95%CI 1.2-8.8; P =.02) and presence of microvascular complications (adjusted OR 4.2, 95%CI 1.5-11.4; P =.005), mainly CKD (adjusted OR 3.6, 95%CI 1.3-10.1; P =.01) and retinopathy (adjusted OR 3.7, CI 95% 1.2-11.9; P =.02). Neither diabetes duration nor haemoglobin A1c differed according to CAP or LSM values. Conclusion: Significant fibrosis, detected by FibroScan®, is independently associated with increased prevalence of macrovascular and microvascular complications, thus opening a new scenario in the use of this tool for a comprehensive evaluation of hepatic and vascular complications in patients with T2DM.
Liver fibrosis by FibroScan® independently of established cardiovascular risk parameters associates with macrovascular and microvascular complications in patients with type 2 diabetes / R. Lombardi, L. Airaghi, G. Targher, G. Serviddio, G. Maffi, A. Mantovani, C. Maffeis, A. Colecchia, R. Villani, L. Rinaldi, E. Orsi, G. Pisano, L.E. Adinolfi, S. Fargion, A.L. Fracanzani. - In: LIVER INTERNATIONAL. - ISSN 1478-3223. - 40:2(2020 Feb), pp. 347-354. [10.1111/liv.14274]
Liver fibrosis by FibroScan® independently of established cardiovascular risk parameters associates with macrovascular and microvascular complications in patients with type 2 diabetes
R. Lombardi;E. Orsi;S. Fargion;A.L. Fracanzani
2020
Abstract
Background & Aims: Non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes mellitus (T2DM) are closely associated, and liver fibrosis has been related to macrovascular complications. We examined whether liver fibrosis, diagnosed by FibroScan®, correlates with chronic vascular complications in a cohort of T2DM. Methods: We recruited 394 outpatients with T2DM attending five Italian diabetes centres who underwent liver ultrasonography (US), FibroScan® and extensive evaluation of macrovascular and microvascular diabetic complications. Results: Steatosis by US was present in 89%. Almost all patients (96%) were on hypoglycaemic drugs, 58% had at least one chronic vascular complication, 19% a macrovascular complication (prior myocardial infarction and/or ischaemic stroke) and 33% a microvascular one (26% chronic kidney disease [CKD]; 16% retinopathy; 6% neuropathy). In all, 171 (72%) patients had CAP ≥ 248dB/m (ie hepatic steatosis), whereas 83 (21%) patients had LSM ≥ 7.0/6.2 kPa (M/XL probes) (significant liver fibrosis). CAP was not associated with any macro/microvascular complications, whereas LSM ≥ 7.0/6.2 kPa was independently associated with prior cardiovascular disease (adjusted OR 3.3, 95%CI 1.2-8.8; P =.02) and presence of microvascular complications (adjusted OR 4.2, 95%CI 1.5-11.4; P =.005), mainly CKD (adjusted OR 3.6, 95%CI 1.3-10.1; P =.01) and retinopathy (adjusted OR 3.7, CI 95% 1.2-11.9; P =.02). Neither diabetes duration nor haemoglobin A1c differed according to CAP or LSM values. Conclusion: Significant fibrosis, detected by FibroScan®, is independently associated with increased prevalence of macrovascular and microvascular complications, thus opening a new scenario in the use of this tool for a comprehensive evaluation of hepatic and vascular complications in patients with T2DM.File | Dimensione | Formato | |
---|---|---|---|
liv.14274 (1).pdf
accesso riservato
Tipologia:
Publisher's version/PDF
Dimensione
531.12 kB
Formato
Adobe PDF
|
531.12 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.